The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Steatosis: An Independent Risk Factor for Fibrosis in Chronic HCV

Steatosis is an independent risk factor for fibrosis in African-Americans with chronic HCV infection. A study recently published in Digestive Disease Science found that hypertension, older age, obesity, and HIV are risk factors and that steatosis is an independent risk factor for liver fibrosis in African-Americans with chronic hepatitis C. "Our retrospective study showed that there are risk factors, such as HIV coinfection for progression of liver fib

HCV-related cirrhosis prevalence increases over time

“Most patients with chronic hepatitis C infection are asymptomatic,” Kim said. “Importantly, the proportion of people with cirrhosis was the same between hepatitis C positive individuals who were aware of their infection and those who were not,” adding that chronic HCV is now curable, therefore improved outcome can be expected from a prompt screening and appropriate treatments. The rate of cirrhosis found among patients with hepatitis C virus infection in